MA-WHOOP
13.5.2024 12:01:35 CEST | Business Wire | Press release
WHOOP, the human performance company, today announced Cristiano Ronaldo, the legendary football icon, as an official global ambassador and investor. This represents one of Ronaldo's most significant investments to date. Ronaldo joins the company’s growing roster of global ambassador investors, including Patrick Mahomes, Michael Phelps, Eli Manning, Rory McIlroy, and more. Announced earlier this morning on Instagram Live, this partnership signifies the company’s global growth trajectory and commitment to revolutionizing the world of human performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513817139/en/
WHOOP announces global partnership with Cristiano Ronaldo. (Photo: Business Wire)
The partnership between WHOOP and Ronaldo is an obvious one. Ronaldo’s success has been built on an obsession to perform at the highest levels. First to training, last to leave - former teammates speak of his dedication to self improvement having been the driving force behind his success. Cristiano is still performing at a very high level. He was the highest scorer in the World in 2023, is currently the top scorer in the Saudi Pro League, and is preparing for the Euros this summer. Ronaldo and WHOOP will partner on product development and leverage data-driven insights to help deliver the best health and fitness coaching for athletes and humanity broadly.
“Cristiano has been a WHOOP member for a number of years, and we’re proud to strengthen our relationship further through this partnership,” said Will Ahmed, WHOOP Founder and CEO. “Cristiano’s relentless pursuit of improvement and perfection mirrors our mission. We are looking forward to collaborating with him to share unprecedented insights into his training and recovery methods. Together, we'll unveil exciting product collaborations to enhance the WHOOP experience for our members.”
Cristiano Ronaldo, one of the greatest players in the history of football, has achieved unparalleled success across various prestigious football leagues worldwide, including the Premier League (Manchester United 2003-09; 2021-23), LaLiga (Real Madrid 2009-18), Serie A (Juventus 2018-22), and most recently, the Saudi Pro League (Al Nassr 2022-Present). As the leading scorer in the history of top-level association football globally, with 891 goals and counting, Ronaldo has won seven league titles and five UEFA Champions Leagues and is a five-time winner of the Ballon d'Or.
Ronaldo has also represented his home country of Portugal in international competition with the senior team since 2003, appearing in 206 matches to date and scoring 128 goals. His contributions have led Portugal to victory in the UEFA European Championship in 2016 and the UEFA Nations League title in 2019.
“WHOOP has had a transformative impact on my life both on and off the pitch, and I’m honored to join the team as an investor,” said Cristiano Ronaldo. “I wear WHOOP while training, sleeping, and recovering. It’s been one of the most important tools helping me elevate my game and monitor my health. I look forward to working with WHOOP to continue to raise the bar on WHOOP features and coaching.”
The partnership and investment from Ronaldo coincide with the announcement of WHOOP expanding its availability to Gulf Cooperation Council regions - Saudi Arabia, Qatar, Kuwait, Bahrain - in addition to Hong Kong, Israel, Korea, and Taiwan. Furthermore, by the time of the announcement, WHOOP will have extended its shipping services to India, Mexico, and Brazil, ensuring a seamless experience for members across these markets.
For more information on WHOOP x Ronaldo, please visit www.whoop.com/cr7.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513817139/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom